A carregar...
Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models
BACKGROUND: Lurbinectedin is a novel anticancer agent currently undergoing late-stage (Phase II /III) clinical evaluation in platinum-resistant ovarian, BRCA1/2-mutated breast and small-cell lung cancer. Lurbinectedin is structurally related to trabectedin and it inhibits active transcription and th...
Na minha lista:
| Publicado no: | Br J Cancer |
|---|---|
| Main Authors: | , , , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Nature Publishing Group
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5572168/ https://ncbi.nlm.nih.gov/pubmed/28683469 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2017.205 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|